Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174370
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bach Griera, Marc | - |
dc.contributor.author | Campo Pérez, Víctor | - |
dc.contributor.author | Barbosa, Sandra | - |
dc.contributor.author | Traserra, Sara | - |
dc.contributor.author | Guallar Garrido, Sandra | - |
dc.contributor.author | Moya Andérico, Laura | - |
dc.contributor.author | Herrero Abadía, Paula | - |
dc.contributor.author | Luquin, Marina | - |
dc.contributor.author | Rabanal Prados, Rosa Ma. (Rosa Maria) | - |
dc.contributor.author | Torrents Serra, Eduard | - |
dc.contributor.author | Julián, Esther | - |
dc.date.accessioned | 2021-02-25T18:11:38Z | - |
dc.date.available | 2021-02-25T18:11:38Z | - |
dc.date.issued | 2020-04-25 | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.uri | http://hdl.handle.net/2445/174370 | - |
dc.description.abstract | Intravesical Mycobacterium bovis Bacillus Calmette-Guérin (BCG) immunotherapy remains the gold-standard treatment for non-muscle-invasive bladder cancer patients, even though half of the patients develop adverse events to this therapy. On exploring BCG-alternative therapies, Mycolicibacterium brumae, a nontuberculous mycobacterium, has shown outstanding anti-tumor and immunomodulatory capabilities. As no infections due to M. brumae in humans, animals, or plants have been described, the safety and/or toxicity of this mycobacterium have not been previously addressed. In the present study, an analysis was made of M. brumae- and BCG-intravenously-infected severe combined immunodeficient (SCID) mice, M. brumae-intravesically-treated BALB/c mice, and intrahemacoelic-infected-Galleria mellonella larvae. Organs from infected mice and the hemolymph from larvae were processed to count bacterial burden. Blood samples from mice were also taken, and a wide range of hematological and biochemical parameters were analyzed. Finally, histopathological alterations in mouse tissues were evaluated. Our results demonstrate the safety and non-toxic profile of M. brumae. Di erences were observed in the biochemical, hematological and histopathological analysis between M. brumae and BCG-infected mice, as well as survival curves rates and colony forming units (CFU) counts in both animal models. M. brumae constitutes a safe therapeutic biological agent, overcoming the safety and toxicity disadvantages presented by BCG in both mice and G. mellonella animal models. | - |
dc.format.extent | 18 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/vaccines8020198 | - |
dc.relation.ispartof | Vaccines, 2020, vol. 8(2), num. 198 | - |
dc.relation.uri | https://doi.org/10.3390/vaccines8020198 | - |
dc.rights | cc-by (c) Bach Griera, Marc et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Genètica, Microbiologia i Estadística) | - |
dc.subject.classification | Àcids grassos | - |
dc.subject.classification | Càncer | - |
dc.subject.other | Fatty acids | - |
dc.subject.other | Cancer | - |
dc.title | Mycolicibacterium brumae is a safe and non-toxic immunomodulatory agent for cancer treatment | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 701803 | - |
dc.date.updated | 2021-02-25T18:11:38Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 32344808 | - |
Appears in Collections: | Articles publicats en revistes (Genètica, Microbiologia i Estadística) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
701803.pdf | 2.64 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License